Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis.

Abstract

A 73-year-old female, who suffered from rheumatoid arthritis for 10 years, developed precore mutant hepatitis B virus-associated fulminant hepatitis after 1 year of infliximab therapy and subsequent methotrexate withdrawal. We emphasize the importance of preemptive antiviral therapy before starting infliximab administration and withdrawing immunosuppressive drugs.

• Authors: Hiroko Kuwabara, Akira Fukuda, Yasuhiro Tsuda, Yuro Shibayama
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 32 Suppl 1 Pg. S47-9 (Mar 2013) ISSN: 1434-9949 [Electronic] Germany
• PMID: 20379839 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• DNA, Viral
• Hepatitis B Core Antigens
• Immunosuppressive Agents
• Infliximab
• Methotrexate

Topics

• Aged
• Antibodies, Monoclonal (adverse effects)
• Antirheumatic Agents (adverse effects)
• Arthritis, Rheumatoid (immunology, pathology, virology)
• DNA, Viral (analysis)
• Drug Therapy, Combination
• Fatal Outcome
• Female
• Hepatitis B (complications, immunology, pathology)
• Hepatitis B Core Antigens (blood, immunology)
• Hepatitis B virus (genetics, immunology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Infliximab
• Methotrexate (therapeutic use)
• Mutation
• Withholding Treatment